Delivery Order SPE2DB22D1202-SPE2DB25FVHZ4
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Multaq 400 mg tablets (60-count) valued at $9,625.47 under a firm fixed-price contract. This non-set-aside award represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. AmerisourceBergen, headquartered in...
- The Defense Logistics Agency awarded a $1,232.98 firm fixed price delivery order to AmerisourceBergen Drug Corp on May 16, 2025, for the supply of Multaq (dronedarone) 400 mg tablets in a quantity of 60 units. The contract, which is not set-aside, has an ultimate completion date of May 19, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under a larger indefinite delivery vehicle that...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Multaq 400 mg tablets (60-count units) with a ceiling value of $8,201.13. This firm fixed-price delivery order, which is scheduled for completion by August 19, 2025, represents a competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Multaq 400 mg tablets (60-count units) valued at $24,960.51 with firm fixed pricing. This competitively awarded, non-set-aside contract is scheduled for completion by September 15, 2025, with performance of work occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,871.00 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Multaq 400 mg tablets (60-count units) on August 1, 2025, with an ultimate completion date of August 4, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,529.88 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units). This firm fixed-price delivery order, awarded on August 19, 2025, with an ultimate completion date of August 20, 2025, represents a competitively awarded contract with no set-aside designation. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Multaq (dronedarone) 400 mg tablets in quantities of 60 units. This firm fixed-price delivery order has a ceiling value of $19,914.33 and an ultimate completion date of September 11, 2025. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Multaq is an...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Multaq 400 mg tablets (60-count units) valued at $11,602.70. This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion on April 25, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under the vendor's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Multaq 400 mg tablets (60-count units) with a ceiling value of $14,905.69. This firm fixed-price delivery order, with an ultimate completion date of August 8, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Multaq 400 mg tablets (60-count units) with a ceiling value of $1,959.09. This firm fixed-price delivery order, with an ultimate completion date of May 13, 2025, represents a non-competitive procurement executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical distributor will fulfill this order from its...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVHZ4Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Multaq 400 mg tablets (60-count packaging) with a ceiling value of $7,225.78. This firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The award was made through open competition with no set-aside designation, and the pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The ultimate completion date for this delivery order is August 22, 2025. Multaq (dronedarone) is an antiarrhythmic medication used in military and veteran healthcare systems to manage atrial fibrillation. This delivery order exemplifies AmerisourceBergen's role as a critical prime vendor within DLA's pharmaceutical supply chain, fulfilling targeted medical procurement needs across the Defense Health Agency and other federal healthcare systems. As a major pharmaceutical distributor, AmerisourceBergen maintains an extensive portfolio of brand-name and generic medications across multiple therapeutic domains, enabling the company to serve as a comprehensive healthcare solutions provider for federal medical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.2k | 8/21/25 |